Related Experiment Videos
[Clinical evaluation of biapenem (L-627) in children]
K Fujita1, M Yoshikawa, K Murono
1Department of Pediatrics, Asahikawa Medical College.
Insights
Biapenem (L-627) demonstrated significant clinical efficacy in pediatric patients with various infections, including pneumonia and urinary tract infections. The antibiotic was generally well-tolerated, with only minor side effects observed in a small number of children.
Area of Science:
- Pediatric Infectious Diseases
- Antibiotic Therapy
- Clinical Pharmacology
Background:
- Bacterial infections pose a significant health challenge in pediatric populations.
- Novel antimicrobial agents are crucial for combating resistant pathogens and improving treatment outcomes.
- Biapenem (L-627) is a carbapenem antibiotic with broad-spectrum activity.
Purpose of the Study:
- To evaluate the clinical efficacy of biapenem (L-627) in pediatric patients.
- To assess the safety and tolerability profile of biapenem (L-627) in children.
- To determine the effectiveness of biapenem (L-627) across various pediatric infections.
Main Methods:
- A cohort of 24 pediatric patients with diverse bacterial infections received biapenem (L-627).
- Treatment involved doses ranging from 5.5-12.4 mg/kg every 8 hours for 2.67 to 11.33 days.
- Clinical response and adverse events were systematically monitored.
Main Results:
- Biapenem (L-627) showed positive clinical responses in children with pneumonia (11), urinary tract infections (6), cellulitis (2), scarlet fever (1), and cervical lymphadenitis (1).
- Overall, 13 out of 21 evaluated children achieved excellent outcomes, and 8 had good outcomes.
- The antibiotic was well-tolerated, with transient, mild elevations in serum transaminases noted in 2 patients.
Conclusions:
- Biapenem (L-627) is an effective therapeutic option for treating a range of bacterial infections in children.
- The safety profile of biapenem (L-627) in pediatric patients is favorable, with minimal adverse effects.
- Further research may explore its role in specific pediatric infectious disease contexts.
Abstract:
Twenty-four children were treated with biapenem (L-627) and the clinical efficacy and side effects were evaluated. The ages of the patients ranged from two months to 11.5 years and their body weights from 5.9 to 43.5 kg. Doses given were 5.5-12.4 mg/kg every 8 hours for 2.67 to 11.33 days. Those patients who responded well to L-627 treatment included 11 children with pneumonia, 1 with scarlet fever, 1 with cervical lymphadenitis, 2 with cellulitis, 6 with urinary tract infection. Among 21 children, the results were excellent in 13 and good in 8. The drug was well tolerated, although slightly elevated serum concentrations of transaminases occurred in 2 patients among the 24 patients.